Press Release

G2GBio has the best experts in the field of innovative improved injectable drug development.

G2GBio has been selected as an "international collaborative technology development operator" along with Micropore Technologies from the UK.
2022.10.07
HIT 485

G2GBio has been selected as an "international collaborative technology development operator" along with Micropore Technologies from the UK. 

 

 

 

(Photo, from the left, CEO of Micropore Hayward, CEO of G2GBIO Lee Heeyong)

 

G2GBio, a drug delivery technology company, announced on the 7th that it has been selected as an "international collaborative technology development operator" along with Micropore Technologies based in the UK, to receive funding support from the governments of both South Korea and the UK for the development of a continuous large-scale production system for microsphere injectables.

 

Under the technology development agreement, Micropore Technologies will develop a two-stage continuous microsphere manufacturing system incorporating real-time Process Analytical Technology (PAT) based on G2GBio's research and feedback. G2GBio, in collaboration with Micropore Technologies, will be responsible for the development of cGMP-level microsphere mass production and evaluation technologies using the continuous microsphere manufacturing system.

 

The joint technology development project, supported by a research budget of 1.8 billion won, is scheduled to commence in November. 

G2GBio has already been utilizing Micropore Technologies’ membrane equipment in its GMP production process since 2020, enabling the mass production of uniform microspheres. With the completion of this joint development, G2GBio will secure cGMP facilities and implement PAT for continuous microsphere production.

 

Furthermore, it is expected that by developing a continuous microsphere manufacturing system capable of real-time quality assessment, a foundation for economically producing high-quality pharmaceuticals will be established. 

 

Micropore Technologies is a company with world-class expertise in membrane-based technologies for sustained microspheres and LNP (lipid nanoparticle) production in cGMP settings. G2GBio has been conducting various tests on the GMP production line of sustained-release microsphere injections using Micropore Technologies’ equipment.

 

Heeyong Lee, the CEO of G2GBio, stated, "We have already established a significant technological advantage over our competitors with the currently secured microsphere production system." He further added, "Through this joint development project, with the establishment of a continuous large-scale production system, we will gain a distinctive competitive edge in the field of sustained-release microsphere injectables."

 

Dai Hayward, the CEO of Micropore Technologies, expressed his delight at being selected as a supported partner by both governments, stating, "We expect our business collaboration with G2GBio to expand significantly as a result of this collaboration."

 

cGMP (Current Good Manufacturing Practice) refers to the quality management standards recognized by the US Food and Drug Administration (FDA). Bio-pharmaceutical factories must comply with cGMP regulations, starting from the design phase and continuing through facility construction, equipment, documentation, personnel, and all other elements involved in production before commencing manufacturing activities.